Avinger, Inc. (NASDAQ:AVGR)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $1.45, but opened at $1.30. Avinger shares last traded at $1.21, with a volume of 339,946 shares trading hands.

Several equities research analysts have issued reports on the company. Zacks Investment Research downgraded Avinger from a “buy” rating to a “hold” rating in a report on Monday, November 9th. Aegis dropped their price objective on Avinger from $1.40 to $1.00 and set a “buy” rating on the stock in a report on Wednesday, September 16th.

The company has a market cap of $95.96 million, a price-to-earnings ratio of -0.86 and a beta of 2.03. The firm has a 50-day moving average price of $0.46 and a 200 day moving average price of $0.39. The company has a current ratio of 1.72, a quick ratio of 1.50 and a debt-to-equity ratio of 0.06.

Avinger (NASDAQ:AVGR) last issued its earnings results on Sunday, November 15th. The medical device company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. The company had revenue of $2.30 million during the quarter. Avinger had a negative return on equity of 234.16% and a negative net margin of 226.95%. Research analysts anticipate that Avinger, Inc. will post -0.79 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in Avinger during the 3rd quarter worth $31,000. Perkins Capital Management Inc. bought a new stake in shares of Avinger in the 3rd quarter worth $757,000. Finally, Spectrum Asset Management Inc. NB CA bought a new stake in shares of Avinger in the 3rd quarter worth $258,000. Institutional investors own 5.34% of the company’s stock.

About Avinger (NASDAQ:AVGR)

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Featured Article: What economic reports are most valuable to investors?

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.